Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) currently has an Average Broker Rating of 2.29. This number is based on the 7 sell-side firms polled by Zacks. The ABR rank within the industry stands at 15. Analysts on a consensus basis are expecting that the stock will reach $7.17 within the year. The ABR is provided by Zacks which simplfies analyst ratings into an integer based number. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating.
An evaluation of a stock’s expected performance and/or its risk level as judged by a rating agency such as Standard and Poor’s. A stock rating will usually tell the investor how well a stock’s market value relates to what analysts believe is a fair value for the stock, based on an objective evaluation of the company. The greater the amount by which the fair value exceeds the market value, the more highly recommended a buy the stock is. Conversely, if the market value of the stock exceeds the fair value of the stock, then analysts recommend that the stock be sold.
Research analysts are predicting that Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will report earnings of $-0.17 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
With equity investing, there will constantly be worries and fears. The volatility in the market that accompanies these fears may trick investors into thinking the next bear market is on the doorstep. During a market-wide sell off, many stocks may experience the pain. Over time, many may gain back the ground they lost and return to previous levels. The biggest names may be the ones to recoup the losses the quickest. However, many investors might get stuck waiting for a rebound that just isn’t going to happen. Having the flexibility to adapt to market conditions may help repair a damaged portfolio. Sometimes a readjustment may be needed in order to regain some confidence. As the next round of earnings reports start to come in, investors will be keeping a close watch to see which companies produce the largest surprises, both positive and negative.
Most recently Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted quarterly earnings of $-0.21 which compared to the sell-side estimates of -0.18. The stock’s 12-month trailing earnings per share stands at $-1.34. Shares have moved $7.33 over the past month and more recently, $2.33 over the past week heading into the earnings announcement. There are 5 analyst projections that were taken into consideration from respected brokerage firms.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) closed the last session at $6.59 and sees an average of 983631.88 shares trade hands in each session. The 52-week low of the stock stands at $4.1 while the current level stands at 72.6% of the 52-week High-Low range. Looking further out we can see that the stock has moved 20.92% over the past 12 weeks and 12.46% year to date.
3 analysts rate Keryx Biopharmaceuticals, Inc. a Buy or Strong Buy, which is 42.86% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.